Cure My Disease

Don't miss your cure!

 Log in / Sign up

Bypass or stent? study settles debate for tough heart blockage

NCT ID NCT07373678

Disease control Sponsor: Mersin Medicalpark Hastanesi Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at 302 people with a completely blocked left anterior descending artery, a key heart vessel. Researchers compared two standard treatments: bypass surgery (CABG) and stenting (PCI). The goal was to see which procedure works better and has fewer complications in the short and medium term. Results will help doctors choose the best option for this specific type of heart disease.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Coronary artery bypass grafting and percutaneous coronary intervention (stenting)
What this could lead to
If one approach proves clearly better, it could guide doctors toward the safest, most effective treatment for this specific type of heart blockage.
What could go wrong
This is a completed observational study, not a randomized trial, so results may be influenced by patient selection. Also, it focuses on a narrow patient group, so findings may not apply broadly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

302 people

The number who actually took part.

Started

Sep 2025

Finished

Jan 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population consists of adult patients aged 18 years or older with isolated chronic total occlusion (CTO) of the left anterior descending (LAD) coronary artery who underwent coronary revascularization with either coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI) as part of routine clinical care. Isolated LAD CTO was defined as a de novo or in-stent total occlusion confined to the LAD artery, without significant coronary artery disease (≥50% stenosis) in other major epicardial coronary arteries. Patients with prior coronary revascularization, multiple CTOs, severe left ventricular dysfunction, or incomplete follow-up data were excluded.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 years or older at the time of the index procedure. * Diagnosis of isolated chronic total occlusion (CTO) of the left anterior descending (LAD) coronary artery. * Isolated LAD CTO defined as a de novo or in-stent total occlusion confined to the LAD artery, without significant coronary artery disease (defined as ≥50% stenosis) in other major epicardial coronary arteries, including the left circumflex (LCx), right coronary artery (RCA), or major side branches. * No prior percutaneous coronary intervention (PCI) performed in non-LAD coronary arteries. * Patients who underwent coronary revascularization with either coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI) for isolated LAD CTO. Exclusion Criteria: * History of malignancy or active malignant disease at the time of the index procedure. * Prior coronary artery bypass grafting (CABG) or prior percutaneous coronary intervention (PCI) performed in non-LAD coronary arteries. * Presentation with ST-segment elevation myocardial infarction (STEMI). * Discontinuation of prescribed medical therapy by patient preference within one year after the index procedure. * Presence of multiple chronic total occlusions (CTOs) involving more than one coronary artery. * Significant side branch disease of the LAD requiring two bypass grafts. * Performance of crossover stenting from the LAD into the left main coronary artery during LAD CTO-PCI. * Treatment of LAD CTO with drug-eluting balloon (DEB) angioplasty without stent implantation. * Left ventricular ejection fraction (LVEF) less than 30%. * Presence of severe valvular heart disease (e.g., severe aortic or mitral stenosis or regurgitation). * Incomplete angiographic or clinical follow-up data. * Use of mechanical circulatory support devices due to advanced heart failure, including intra-aortic balloon pump (IABP), extracorporeal membrane oxygenation (ECMO), or left ventricular assist device (LVAD).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic total occlusion are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic total occlusion

Contacts and locations

Locations

  • Sefa SURAL

    Mersin, 33010, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.